Results 51 to 60 of about 4,171 (150)
This review synthesizes epidemiological evidence linking atopic dermatitis to attention‐deficit/hyperactivity disorder in children, proposes an “inflammation‐itch‐neurobehavioral axis” integrating sleep disruption, neuroendocrine dysregulation, and emerging neuro‐immune circuits, and outlines multidisciplinary management strategies targeting both skin ...
Qingyang Zhao +11 more
wiley +1 more source
Substance P (SP) and its receptor neurokinin 1 (NK1R) are thought to be involved in the pathogenesis of chronic prurigo. Here, we assessed SP serum levels, cutaneous NK1R expression, and the effects of topical aprepitant, an NK1R antagonist, in patients ...
Tatevik Ohanyan +7 more
doaj +1 more source
The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith +9 more
wiley +1 more source
Thalidomide for the treatment of chronic refractory prurigo nodularis [PDF]
Prurigo nodularis (PN) is a highly pruritic skin condition that is caused by chronic scratching. It occurs in patients with chronic itch and is characterized by multiple hyperkeratotic papules and nodules. The pathogenesis of PN is unclear, but involves a complex interplay of numerous pathways including neurogenic and inflammatory factors.
Aguh, Crystal +3 more
openaire +4 more sources
Biopsychosocial factors associated with prurigo nodularis in endogenous eczema
Background: Prurigo nodularis is a dermatological manifestation secondary to chronic scratching or picking on focal areas of the skin. Its pathogenesis remains poorly understood, and limited data has indicated its association with psychological factors ...
Choon Chiat Oh +3 more
doaj +1 more source
Dupilumab improved all histological, symptomatic, and endoscopic outcomes assessed at Week 24 versus placebo in patients with eosinophilic oesophagitis, regardless of demographics, disease characteristics, treatment history, or type 2 inflammatory disease comorbidities.
Evan S. Dellon +7 more
wiley +1 more source
Recalcitrant prurigo nodularis after COVID‐19 vaccination and successfully treated by dupilumab
Prurigo nodularis (PN) is a chronic, inflammatory skin condition characterized by the presence of pruritic nodules. We report a 57‐year‐old woman in whom PN might have been induced by COVID‐19 vaccination. PN lesions started 2 days after she received the
Shang‐shang Wang +2 more
doaj +1 more source
Summary Background and Objectives Atopic dermatitis (AD) has a highly variable clinical phenotype and ancestry can contribute to this heterogeneity. This study aims to identify clinical phenotypes of AD in children from diverse ancestry groups, evaluate clinical outcomes and response to treatment, and define phenotypic clusters with potential relevance.
Eugeni Prat‐Colilles +21 more
wiley +1 more source
Summary Background and objectives Chronic pruritus (CP) significantly impairs quality of life (QoL), but existing patient‐reported QoL tools are either not specific for CP or are very extensive. Patients and methods The 5‐item pruritus life quality (5PLQ, range: 5–25, 7‐day recall) was developed to assess key itch‐related QoL domains (sensory symptoms,
Claudia Zeidler +14 more
wiley +1 more source
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs.
Athanasios Tsianakas +12 more
doaj +1 more source

